SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-002951 to GRI Bio, Inc. (GRI)

GRI Bio, Inc.
Date: March 18, 2025 · CIK: 0001824293 · Accession: 0000000000-25-002951

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
March 18, 2025
Author
Division of
Form
UPLOAD
Company
GRI Bio, Inc.

Letter

Re: GRI Bio, Inc. Draft Registration Statement on Form S-1 Submitted March 14, 2025 CIK No. 0001824293 Dear W. Marc Hertz:

March 18, 2025

W. Marc Hertz President and Chief Executive Officer GRI Bio, Inc. 2223 Avenida de la Playa, #208 La Jolla, CA 92037

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jason Miller, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 18, 2025

W. Marc Hertz
President and Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa, #208
La Jolla, CA 92037

 Re: GRI Bio, Inc.
 Draft Registration Statement on Form S-1
 Submitted March 14, 2025
 CIK No. 0001824293
Dear W. Marc Hertz:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement no later
than 48 hours
prior to the requested effective date and time. Please refer to Rules 460 and
461 regarding
requests for acceleration. We remind you that the company and its management
are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jason Miller, Esq.
</TEXT>
</DOCUMENT>